original ) (raw )Modified oligonucleotides: IV solid phase synthesis and preliminary evaluation of phosphorothioate RNA as potential antisense agents
Francois Morvan
Tetrahedron Letters, 1990
View PDFchevron_right
The therapeutic potential of antisense oligonucleotides
Ramaswamy Narayanan
BioEssays, 1995
View PDFchevron_right
RNase H-independent antisense activity of oligonucleotide N34P54 phosphoramidates
Sergei Gryaznov
Nucleic Acids Research - NAR
View PDFchevron_right
Mixed-Backbone oligonucleotides as second-generation antisense agents with reduced phosphorothioate-related side effects
Carl Saxinger
Bioorganic & Medicinal Chemistry Letters, 1998
View PDFchevron_right
Mesyl Phosphoramidate Oligonucleotides: A New Promising Type of Antisense Agents
Dmitry Stetsenko
2023
View PDFchevron_right
Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 24-54-ribo- and 34-54-deoxyribonucleotide segments
adrienne manning
View PDFchevron_right
Mesyl phosphoramidate backbone modified antisense oligonucleotides targeting miR-21 with enhanced in vivo therapeutic potency
Valentin Vlasov
Proceedings of the National Academy of Sciences of the United States of America, 2020
View PDFchevron_right
Oligonucleotide N3'-->P5' phosphoramidates as antisense agents
Sergei Gryaznov
Nucleic Acids Research, 1996
View PDFchevron_right
Abstracts from the Fourth Annual NIH Symposium on Therapeutic Oligonucleotides: Antisense and DNA Chips
Igor Panyutin
Antisense and Nucleic Acid Drug Development, 2000
View PDFchevron_right
Therapeutic implications of antisense oligonucleotides
M. Mazzei
International Journal of Clinical & Laboratory Research, 1992
View PDFchevron_right
Antisense oligodeoxynucleotides: synthesis, biophysical and biological evaluation of oligodeoxynucleotides containing modified pyrimidines
Yogesh Sanghvi
Nucleic Acids Research, 1993
View PDFchevron_right
Antisense Oligonucleotides, A Novel Developing Targeting Therapy
Palma Rocchi
Antisense Therapy [Working Title]
View PDFchevron_right
Partial protection of oncogene, anti-sense oligodeoxynucleotides against serum nuclease degradation using terminal methylphosphonate groups
Hilmar Warenius
British journal of cancer, 1989
View PDFchevron_right
Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development
Karishma Dhuri
Journal of Clinical Medicine
View PDFchevron_right
Nuclear antisense effects of neutral, anionic and cationic oligonucleotide analogs
Ryszard Kole
Nucleic acids research, 2001
View PDFchevron_right
The Combination of Mesyl-Phosphoramidate Inter-Nucleotide Linkages and 2′-O-Methyl in Selected Positions in the Antisense Oligonucleotide Enhances the Performance of RNaseH1 Active PS-ASOs
Lingdi Zhang
Nucleic Acid Therapeutics
View PDFchevron_right
Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA
Jens Kurreck
Nucleic Acids Research, 2003
View PDFchevron_right
Comparative inhibition of chloramphenicol acetyltransferase gene expression by antisense oligonucleotide analogues having alkyl phosphotriester, methylphosphonate and phosphorothioate linkages
Gerald Zon
Nucleic Acids Research, 1987
View PDFchevron_right
Therapeutic antisense oligonucleotides against cancer: hurdling to the clinic
Pedro Moreno
View PDFchevron_right
In vitro and in vivo properties of therapeutic oligonucleotides containing non-chiral 3′ and 5′ thiophosphate linkages
Erich Koller
Nucleic Acids Research, 2019
View PDFchevron_right
Potent and nontoxic antisense oligonucleotides containing locked nucleic acids
Michael Ossipov
Proceedings of The National Academy of Sciences, 2000
View PDFchevron_right
Antisense Oligonucleotides Containing Conformationally Constrained 2′,4′-( N Methoxy)aminomethylene and 2′,4′-Aminooxymethylene and 2′- O ,4′- C -Aminomethylene Bridged Nucleoside Analogues Show Improved Potency in Animal Models
Chris Black
Journal of Medicinal Chemistry, 2010
View PDFchevron_right
Short Antisense Oligonucleotides with Novel 2′−4′ Conformationaly Restricted Nucleoside Analogues Show Improved Potency without Increased Toxicity in Animals
Guillermo Vasquez
Journal of Medicinal Chemistry, 2009
View PDFchevron_right
Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages
sam lee
Nucleic Acids Research, 2014
View PDFchevron_right
Antisense oligonuclotides with oxetane-constrained cytidine enhance heteroduplex stability, and elicit satisfactory RNase H response as well as showing improved resistance to both exo and endonucleasesElectronic supplementary information (ESI) available: RNA cleavage kinetics. See http://www.rsc....
Jyoti Chattopadhyaya
Organic & Biomolecular Chemistry, 2002
View PDFchevron_right
Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules
Cezary Swider
Nucleic Acids Research, 2004
View PDFchevron_right